Sun Pharmaceutical Industries Ltd.
BSE: 524715 | NSE: SUNPHARMA
Large Cap | Pharmaceuticals & Drugs
1924.05
-11.20 (-0.58%) Sun Pharma to sell Ranbaxy’s two CNS divisions for Rs 165 crore
Date: 21-09-2015Sun Pharmaceutical Industries is selling Ranbaxy’s two divisions in Central Nervous System (CNS) segment in India to Strides Arcolab for Rs 165 crore.
The pharma major and Strides have entered into a definitive agreement related to erstwhile Ranbaxy’s ‘Solus’ and ‘Solus Care’ divisions operating in the central nervous system (CNS) segment in India. The agreement involves transfer of these two marketing divisions, along with employees to Strides.
Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.